Los Angeles Capital Management
SPRO icon

Los Angeles Capital Management’s Spero Therapeutics SPRO Stock Holding History

Los Angeles Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-27,960
Closed -$412K – 1663
2021
Q1 		$412K Buy
27,960
+5,703
+26% +$100K ﹤0.01% 1303
2020
Q4 		$432K Sell
22,257
-8,550
-28% -$133K ﹤0.01% 1262
2020
Q3 		$344K Sell
30,807
-5,193
-14% -$61.4K ﹤0.01% 1222
2020
Q2 		$487K Buy
36,000
+20,817
+137% +$234K ﹤0.01% 1116
2020
Q1 		$123K Buy
+15,183
New +$134K ﹤0.01% 1275

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Los Angeles Capital Management's SPRO Position: Q2 2021 in Review

Los Angeles Capital Management sold out of Spero Therapeutics (SPRO) in Q2 2021, closing a stake of 27,960 shares — an estimated $412K sold.

Los Angeles Capital Management first reported a position in SPRO in Q1 2020 and held it in 5 quarters. The position peaked at $487K in Q2 2020. 88 funds tracked by Wall St. Rank hold SPRO as of Q2 2021.

  • Los Angeles Capital Management reported no remaining Spero Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Los Angeles Capital Management sold 27,960 Spero Therapeutics shares in Q2 2021, an estimated $412K.
  • Los Angeles Capital Management first reported a position in Spero Therapeutics in Q1 2020 and held it in 5 quarters.
  • Los Angeles Capital Management's Spero Therapeutics position peaked at $487K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2021.

Based on Los Angeles Capital Management's 13F filing for Q2 2021, filed 5 Aug 2021.